Form 4: VolitionRx Officer Jacob Vincent Micallef Reports Changes in Beneficial Ownership

Jacob Vincent Micallef, Chief Scientific Officer of VolitionRx Ltd, reports changes in beneficial ownership of company stock due to tax withholding obligations upon settlement of restricted stock units.

Summary

• On May 1, 2025, Jacob Vincent Micallef, Chief Scientific Officer of VolitionRx Ltd, reported changes in his beneficial ownership of the company's common stock.
• A total of 18,319 shares were retained by VolitionRx for cancellation to cover tax withholding obligations related to the settlement of 40,709 restricted stock units awarded in lieu of cash compensation.
• The price per share for the transaction is $0.4875.
• Following the transaction, Micallef directly owns 376,033 shares of common stock.
• Micallef also indirectly owns 55,000 shares through his spouse and 38,113 shares through Borlaug Limited, where he is a controlling director.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock transactions for tax purposes, indicating a neutral sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders and their potential impact on stock prices.

Stakeholder Impact

• The transaction may have a minor impact on shareholders due to the cancellation of shares, but it is primarily related to tax obligations of the reporting person.

Key Dates

Keywords

VolitionRx, VNRX, beneficial ownership, Form 4, Micallef, restricted stock units, tax withholding, common stock